Literature DB >> 26503563

Hepatic hemorrhage as a consequence of rapid response to combined targeted therapy in metastatic melanoma.

Devin C Flaherty1, Brianna W Hoffner2, Briana J Lau1, Omid Hamid1,2, Mark B Faries1.   

Abstract

A middle-aged female with metastatic melanoma was found to have hemoperitoneum after starting systemic therapy with the BRAF and MEK inhibitors dabrafenib and trametinib. Etiology proved to be bleeding from a known hepatic metastasis. The patient was managed conservatively and eventually resumed systemic therapy with ongoing response. This case serves to illustrate the possible deleterious effects of rapid tumor response after initiation of targeted systemic therapy in patients with metastatic melanoma.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  BRAF; MEK; dabrafenib; trametinib

Mesh：

Substances：

Year:  2015        PMID： 26503563      PMCID： PMC4976480          DOI： 10.1002/jso.24078

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  9 in total

1.  Improved overall survival in melanoma with combined dabrafenib and trametinib.

Authors:  Caroline Robert; Boguslawa Karaszewska; Jacob Schachter; Piotr Rutkowski; Andrzej Mackiewicz; Daniil Stroiakovski; Michael Lichinitser; Reinhard Dummer; Florent Grange; Laurent Mortier; Vanna Chiarion-Sileni; Kamil Drucis; Ivana Krajsova; Axel Hauschild; Paul Lorigan; Pascal Wolter; Georgina V Long; Keith Flaherty; Paul Nathan; Antoni Ribas; Anne-Marie Martin; Peng Sun; Wendy Crist; Jeff Legos; Stephen D Rubin; Shonda M Little; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  Rapid eradication of a bulky melanoma mass with one dose of immunotherapy.

Authors:  Paul B Chapman; Sandra P D'Angelo; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2015-04-20       Impact factor: 91.245

3.  Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma.

Authors:  Frederic J Kaye; Alison M Ivey; Walter E Drane; William M Mendenhall; Robert W Allan
Journal:  J Natl Cancer Inst       Date:  2014-12-03       Impact factor: 13.506

4.  Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.

Authors:  Georgina V Long; Daniil Stroyakovskiy; Helen Gogas; Evgeny Levchenko; Filippo de Braud; James Larkin; Claus Garbe; Thomas Jouary; Axel Hauschild; Jean-Jacques Grob; Vanna Chiarion-Sileni; Celeste Lebbe; Mario Mandalà; Michael Millward; Ana Arance; Igor Bondarenko; John B A G Haanen; Johan Hansson; Jochen Utikal; Virginia Ferraresi; Nadezhda Kovalenko; Peter Mohr; Volodymr Probachai; Dirk Schadendorf; Paul Nathan; Caroline Robert; Antoni Ribas; Douglas J DeMarini; Jhangir G Irani; Suzanne Swann; Jeffrey J Legos; Fan Jin; Bijoyesh Mookerjee; Keith Flaherty
Journal:  Lancet       Date:  2015-05-31       Impact factor: 79.321

5.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

Authors:  Keith T Flaherty; Jeffery R Infante; Adil Daud; Rene Gonzalez; Richard F Kefford; Jeffrey Sosman; Omid Hamid; Lynn Schuchter; Jonathan Cebon; Nageatte Ibrahim; Ragini Kudchadkar; Howard A Burris; Gerald Falchook; Alain Algazi; Karl Lewis; Georgina V Long; Igor Puzanov; Peter Lebowitz; Ajay Singh; Shonda Little; Peng Sun; Alicia Allred; Daniele Ouellet; Kevin B Kim; Kiran Patel; Jeffrey Weber
Journal:  N Engl J Med       Date:  2012-09-29       Impact factor: 91.245

6.  Drug monographs: dabrafenib and trametinib.

Authors:  J Aubrey Waddell; Dominic A Solimando
Journal:  Hosp Pharm       Date:  2013-11

7.  Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib.

Authors:  Elisa Castellani; Piero Covarelli; Carlo Boselli; Roberto Cirocchi; Antonio Rulli; Francesco Barberini; Daniela Caracappa; Carla Cini; Jacopo Desiderio; Gloria Burini; Giuseppe Noya
Journal:  World J Surg Oncol       Date:  2012-07-30       Impact factor: 2.754

8.  Ruptured hepatic metastases of cutaneous melanoma during treatment with vemurafenib: an autopsy case report.

Authors:  Takuto Nosaka; Katsushi Hiramatsu; Tomoyuki Nemoto; Yasushi Saito; Yoshihiko Ozaki; Kazuto Takahashi; Tatsushi Naito; Kazuya Ofuji; Hidetaka Matsuda; Masahiro Ohtani; Hiroyuki Suto; Yoshiaki Imamura; Yasunari Nakamoto
Journal:  BMC Clin Pathol       Date:  2015-09-03

9.  A case of intracranial hemorrhage caused by combined dabrafenib and trametinib therapy for metastatic melanoma.

Authors:  Le Min Lee; Lynn Feun; Yaohong Tan
Journal:  Am J Case Rep       Date:  2014-10-12
  9 in total
  3 in total

Review 1.  Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.

Authors:  Adil Daud; Katy Tsai
Journal:  Oncologist       Date:  2017-05-18

2.  Dynamic contrast-enhanced MRI coupled with a subtraction technique is useful for treatment response evaluation of malignant melanoma hepatic metastasis.

Authors:  Minsu Lee; Song-Ee Baek; Jieun Moon; Yun Ho Roh; Joon Seok Lim; Mi-Suk Park; Myeong-Jin Kim; Honsoul Kim
Journal:  Oncotarget       Date:  2016-06-21

3.  Acute granulomatous interstitial nephritis in a patient with metastatic melanoma on targeted therapy with dabrafenib and trametinib-A case report.

Authors:  Anna Krelle; Vinod Kalapurackal Mathai; Geoff Kirkland; Louise Nott; Matthew D Jose; Karen Whale
Journal:  Cancer Rep (Hoboken)       Date:  2021-08-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.